



## Clinical trial results:

**Estudio fase II, aleatorizado, abierto, multicéntrico para evaluar la seguridad e inmunogenicidad de la vacuna experimental adyuvada de gripe pandémica H1N1 administrada como primovacunación y booster en niños entre 6 y 35 meses de edad.**

### Summary

EudraCT number	2009-013783-39
Trial protocol	ES
Global end of trial date	24 November 2010

### Results information

Result version number	v3 (current)
This version publication date	20 May 2023
First version publication date	18 April 2015
Version creation reason	<ul style="list-style-type: none"><li>• Correction of full data set</li></ul> Minor corrections in safety section and the addition of an endpoint.

### Trial information

#### Trial identification

Sponsor protocol code	113462
-----------------------	--------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00971321
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Glaxo Smith Kline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, Glaxo Smith Kline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, Glaxo Smith Kline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-000725-PIP01-09
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	18 March 2011
Is this the analysis of the primary completion data?	Yes
Primary completion date	24 November 2010
Global end of trial reached?	Yes
Global end of trial date	24 November 2010
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate whether the haemagglutination-inhibition (HI) immune response to the vaccine-homologous virus of Flu 1 vaccine meets or exceeds the European Medicines Agency, EMEA (Committee for Medicinal Products for Human Use, CHMP) criteria\* 21 days post dose 2 vaccination.

Protection of trial subjects:

Vaccines were administered by qualified and trained personnel. Vaccines were administered only to eligible subjects that had no contraindications to any components of the vaccines.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	10 September 2009
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 157
Worldwide total number of subjects	157
EEA total number of subjects	157

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	157
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0

85 years and over	0
-------------------	---

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

### Period 1

Period 1 title	Final Analysis (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	GSK2340272A Formulation 1 Group

Arm description:

Subjects received two doses of GSK2340272A Formulation 1 vaccine according to a 0, 21-day schedule.

Arm type	Experimental
Investigational medicinal product name	GSK2340272A Formulation 1
Investigational medicinal product code	
Other name	Pandemic influenza vaccine GSK2340272A
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Two primary intramuscular (IM) doses administered in the deltoid region of the arm or in the anterolateral part of the thigh if the subject was < 12 months at study entry, at days 0 and 21.

<b>Arm title</b>	GSK2340272A Formulation 2 Group
------------------	---------------------------------

Arm description:

Subjects received two doses of GSK2340272A Formulation 2 vaccine according to a 0, 21-day schedule.

Arm type	Experimental
Investigational medicinal product name	GSK2340272A Formulation 2
Investigational medicinal product code	
Other name	Pandemic influenza vaccine GSK2340272A
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Two primary intramuscular (IM) doses administered in the deltoid region of the arm or in the anterolateral part of the thigh if the subject was < 12 months at study entry, at days 0 and 21.

<b>Number of subjects in period 1</b>	GSK2340272A Formulation 1 Group	GSK2340272A Formulation 2 Group
Started	104	53
Completed	99	50
Not completed	5	3
Consent withdrawn by subject	5	3



## Baseline characteristics

### Reporting groups

Reporting group title	GSK2340272A Formulation 1 Group
Reporting group description:	
Subjects received two doses of GSK2340272A Formulation 1 vaccine according to a 0, 21-day schedule.	
Reporting group title	GSK2340272A Formulation 2 Group
Reporting group description:	
Subjects received two doses of GSK2340272A Formulation 2 vaccine according to a 0, 21-day schedule.	

Reporting group values	GSK2340272A Formulation 1 Group	GSK2340272A Formulation 2 Group	Total
Number of subjects	104	53	157
Age categorical Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous Units: months			
arithmetic mean	19.3	19.7	
standard deviation	± 9.33	± 8.81	-
Gender categorical Units: Subjects			
Female	43	26	69
Male	61	27	88

## End points

### End points reporting groups

Reporting group title	GSK2340272A Formulation 1 Group
Reporting group description:	
Subjects received two doses of GSK2340272A Formulation 1 vaccine according to a 0, 21-day schedule.	
Reporting group title	GSK2340272A Formulation 2 Group
Reporting group description:	
Subjects received two doses of GSK2340272A Formulation 2 vaccine according to a 0, 21-day schedule.	

### Primary: Haemagglutination inhibition HI antibody titers against Fluarix vaccine containing H1N1 strain

End point title	Haemagglutination inhibition HI antibody titers against Fluarix vaccine containing H1N1 strain <sup>[1][2]</sup>
End point description:	
End point type	Primary
End point timeframe:	
At Day 0 and Day 42	

#### Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This outcome was descriptive; hence no statistical analyses were required.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by the formulation administered to the subject groups. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

End point values	GSK2340272A Formulation 1 Group			
Subject group type	Reporting group			
Number of subjects analysed	101			
Units: Titers				
geometric mean (confidence interval 95%)				
Flu A/CAL/7/2009, Day 0 [N=101]	5.75 (5 to 6.63)			
Flu A/CAL/7/2009, Day 42 [N=97]	2007.7 (1805.24 to 2232.87)			

### Statistical analyses

No statistical analyses for this end point

### Primary: Number of subjects with HI antibody titers $\geq$ 1:10

End point title	Number of subjects with HI antibody titers $\geq$ 1:10 <sup>[3][4]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

At Day 0 and Day 42

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This outcome was descriptive; hence no statistical analyses were required.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by the formulation administered to the subject groups. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

<b>End point values</b>	GSK2340272A Formulation 1 Group			
Subject group type	Reporting group			
Number of subjects analysed	101			
Units: Subjects				
Flu A/CAL/7/2009, Day 0 [N=101]	5			
Flu A/CAL/7/2009, Day 42 [N=97]	97			

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of seroconverted subjects in terms of HI antibodies

End point title	Number of seroconverted subjects in terms of HI antibodies <sup>[5]</sup> <sup>[6]</sup>
-----------------	--

End point description:

Fluarix vaccine strain was Flu A/California/7/2009 (H1N1). A seroconverted subject was a subject who had either a pre-vaccination (Day 0) titre less than ( $<$ ) 1:10 and a post-vaccination titre greater than or equal to ( $\geq$ ) 1:40 or a pre-vaccination titre  $\geq$  1:10 and at least a 4-fold increase in post-vaccination titre for GSK2340272A Formulation 1 Group

End point type	Primary
----------------	---------

End point timeframe:

At Day 42

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This outcome was descriptive; hence no statistical analyses were required.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by the formulation administered to the subject groups. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

<b>End point values</b>	GSK2340272A Formulation 1 Group			
Subject group type	Reporting group			
Number of subjects analysed	97			
Units: Subjects				
Flu A/CAL/7/2009 [Day 42]	97			

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of seroprotected subjects for HI antibodies

End point title	Number of seroprotected subjects for HI antibodies <sup>[7][8]</sup>
-----------------	--

End point description:

Fluarix vaccine strain was Flu A/California/7/2009 (H1N1). A seroprotected subject was a subject with a serum HI titre  $\geq 1:40$  that usually is accepted as indicating protection

End point type	Primary
----------------	---------

End point timeframe:

At Day 42

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This outcome was descriptive; hence no statistical analyses were required.

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by the formulation administered to the subject groups. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

<b>End point values</b>	GSK2340272A Formulation 1 Group			
Subject group type	Reporting group			
Number of subjects analysed	97			
Units: Subjects				
Flu A/CAL/7/2009 [Day 42]	97			

## Statistical analyses

No statistical analyses for this end point

### Primary: Seroconversion factor for HI antibody titre

End point title	Seroconversion factor for HI antibody titre <sup>[9][10]</sup>
-----------------	--

End point description:

Fluarix vaccine strain was Flu A/California/7/2009 (H1N1). A Seroconverted subject was a subject with a serum HI GMTs post-vaccination compared to pre-vaccination. The criterion is fulfilled if the point estimate for SCF was  $> 2.5$  in subjects 18 to 60 years of age for GSK2340272A Formulation 1 Group

End point type	Primary
----------------	---------

End point timeframe:

At Day 42

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This outcome was descriptive; hence no statistical analyses were required.

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The results in this study were tabulated by the formulation administered to the subject groups. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

End point values	GSK2340272A Formulation 1 Group			
Subject group type	Reporting group			
Number of subjects analysed	97			
Units: Fold increase				
geometric mean (confidence interval 95%)				
Flu A/CAL/7/2009 [Day 42]	346.86 (287.54 to 418.42)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: HI antibody titers

End point title	HI antibody titers
End point description:	
End point type	Secondary
End point timeframe:	
At Day 0, Day 21, Day 42 and Months 11-12	

End point values	GSK2340272A Formulation 1 Group	GSK2340272A Formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	83	37		
Units: Titers				
geometric mean (confidence interval 95%)				
Flu A/CAL/7/2009 Day 0 [N=83,37]	5.8 (5 to 6.8)	6.2 (5 to 7.8)		
Flu A/CAL/7/2009 Day 21 [N=83,37]	234 (202.9 to 269.8)	255.5 (205.4 to 317.9)		
Flu A/CAL/7/2009 Day 42 [N=83,37]	1758 (1553.8 to 1989.1)	1879.2 (1504.2 to 2347.7)		

Flu A/CAL/7/2009 Months 11-12 [N=83,37]	212.5 (182.8 to 247)	239.3 (201.6 to 284)		
--	-------------------------	-------------------------	--	--

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with anti-HIs antibody concentrations $\geq$ 1:10

End point title	Number of subjects with anti-HIs antibody concentrations $\geq$ 1:10
End point description:	
End point type	Secondary
End point timeframe:	
At Days 0, 21, 42 and Months 11-12	

End point values	GSK2340272A Formulation 1 Group	GSK2340272A Formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	83	37		
Units: Subjects				
Flu A/CAL/7/2009 Day 0 [N=83,37]	4	4		
Flu A/CAL/7/2009 Day 21 [N=83,37]	83	37		
Flu A/CAL/7/2009 Day 42 [N=83,37]	83	37		
Flu A/CAL/7/2009, Month 11-12 [N=83,37]	83	37		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of seroconverted subjects for HI antibodies

End point title	Number of seroconverted subjects for HI antibodies
End point description:	
End point type	Secondary
End point timeframe:	
At Day 21, Day 42 and Month 11-12	

End point values	GSK2340272A Formulation 1 Group	GSK2340272A Formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	83	37		
Units: Subjects				
Flu A/CAL/7/2009 Day 21 [N=83,37]	82	37		
Flu A/CAL/7/2009 Day 42 [N=83,37]	83	37		
Flu A/CAL/7/2009 Months 11-12 [N=83,37]	81	36		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of seroprotected subjects for HI antibodies

End point title	Number of seroprotected subjects for HI antibodies
End point description:	
End point type	Secondary
End point timeframe:	
At Days 0, 21, 42 and Month 11-12	

End point values	GSK2340272A Formulation 1 Group	GSK2340272A Formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	83	37		
Units: Subjects				
Flu A/CAL/7/2009 Day 0 [N=83,37]	3	3		
Flu A/CAL/7/2009 Day 21 [N=83,37]	83	37		
Flu A/CAL/7/2009 Day 42 [N=83,37]	83	37		
Flu A/CAL/7/2009 Months 11-12 [N=83,37]	83	37		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Seroconversion factor for HI antibody titre

End point title	Seroconversion factor for HI antibody titre
End point description:	
End point type	Secondary
End point timeframe:	
At Day 21, Day 42 and Month 11-12	

<b>End point values</b>	GSK2340272A Formulation 1 Group	GSK2340272A Formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	83	37		
Units: Fold increase				
geometric mean (confidence interval 95%)				
Flu A/CAL/7/2009 Day 21 [N=37;83]	40.3 (34.3 to 47.2)	41.2 (32.2 to 52.7)		
Flu A/CAL/7/2009 Day 42 [N=37;83]	302.5 (248.2 to 368.7)	302.8 (211.8 to 432.9)		
Flu A/CAL/7/2009 Month 11-12 [N=37;83]	36.6 (30 to 44.6)	38.6 (29.5 to 50.4)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Serum neutralising antibody titres

End point title	Serum neutralising antibody titres
End point description:	
End point type	Secondary
End point timeframe:	
At Day 0, Day 21, Day 42 and Month 11-12	

<b>End point values</b>	GSK2340272A Formulation 1 Group	GSK2340272A Formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	57	24		
Units: Titers				
geometric mean (confidence interval 95%)				
Flu A/Neth/602/09 Day 0 [N=57,24]	5.6 (3.9 to 7.9)	5.7 (3.6 to 8.9)		
Flu A/Neth/602/09 Day 21 [N=53,23]	36.9 (24.5 to 55.4)	50.8 (25.6 to 100.7)		
Flu A/Neth/602/09 Day 42 [N=54,23]	1416.1 (1048.1 to 1913.3)	1960.6 (1097 to 3504)		
Flu A/Neth/602/09 Months 11-12 [N=49,22]	312.8 (223.1 to 438.6)	444.4 (286.5 to 689.3)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Vaccine response for neutralising antibodies

End point title Vaccine response for neutralising antibodies

End point description:

End point type Secondary

End point timeframe:

At Day 21, Day 42 and Month 11-12

End point values	GSK2340272A Formulation 1 Group	GSK2340272A Formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	25	12		
Units: Subjects				
Flu A/Neth/602/2009 Day 21 [N=25,12]	14	8		
Flu A/Neth/602/2009 Day 42 [N=25,12]	24	12		
Flu A/Neth/602/2009 Months 11-12 [N=22,10]	19	10		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with solicited local symptoms

End point title Number of subjects with solicited local symptoms

End point description:

End point type Secondary

End point timeframe:

During a 7-day follow-up period, i.e., day of vaccination and six subsequent days after each vaccination.

End point values	GSK2340272A Formulation 1 Group	GSK2340272A Formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	104	53		
Units: Subjects				
Pain Any Dose 1 [N=104,53]	37	31		
Pain Grade 3 Dose 1 [N=104,53]	1	0		
Redness Any Dose 1 [N=104,53]	19	17		
Redness Grade 3 Dose 1 [N=104,53]	0	2		

Swelling Any Dose 1 [N=104,53]	12	11		
Swelling Grade 3 Dose 1 [N=104,53]	0	1		
Pain Any Dose 2 [N=104,52]	43	27		
Pain Grade 3 Dose 2 [N=104,52]	3	2		
Redness Any Dose 2 [N=104,52]	34	23		
Redness Grade 3 Dose 2 [N=104,52]	1	6		
Swelling Any Dose 2 [N=104,52]	30	17		
Swelling Grade 3 Dose 2 [N=104,52]	1	4		
Pain Any Across Doses [N=104,53]	54	37		
Pain Grade 3 Across Doses [N=104,53]	4	2		
Redness Any Across Doses [N=104,53]	41	27		
Redness Grade 3 Across Doses [N=104,53]	1	6		
Swelling Any Across Doses [N=104,53]	38	21		
Swelling Grade 3 Across Doses [N=104,53]	1	5		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with solicited general symptoms

End point title	Number of subjects with solicited general symptoms
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

During a 7-day follow-up period, i.e. day of vaccination and six subsequent days after each vaccination.

End point values	GSK2340272A Formulation 1 Group	GSK2340272A Formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	104	53		
Units: Subjects				
Drowsiness Any Dose 1 [N=104,53]	24	14		
Drowsiness Grade 3 Dose 1 [N=104,53]	0	2		
Drowsiness Related Dose 1 [N=104,53]	17	11		
Irritability Any Dose 1 [N=104,53]	33	17		
Irritability Grade 3 Dose 1 [N=104,53]	2	5		
Irritability Related Dose 1 [N=104,53]	28	12		
Loss of appetite Any Dose 1 [N=104,53]	25	17		
Loss of appetite Grade 3 Dose 1 [N=104,53]	1	1		
Loss of appetite Related Dose 1 [N=104,53]	18	11		
Temperature Any Dose 1 [N=104,53]	21	13		

Temperature Grade 3 Dose 1 [N=104,53]	1	1		
Temperature Related Dose 1 [N=104,53]	16	10		
Drowsiness Any Dose 2 [N=104,52]	36	25		
Drowsiness Grade 3 Dose 2 [N=104,52]	0	2		
Drowsiness Related Dose 2 [N=104,52]	35	22		
Irritability Any Dose 2 [N=104,52]	48	31		
Irritability Grade 3 Dose 2 [N=104,52]	3	4		
Irritability Related Dose 2 [N=104,52]	45	27		
Loss of appetite Any Dose 2 [N=104,52]	44	30		
Loss of appetite Grade 3 Dose 2 [N=104,52]	4	4		
Loss of appetite Related Dose 2 [N=104,52]	41	26		
Temperature Any Dose 2 [N=104,52]	70	37		
Temperature Grade 3 Dose 2 [N=104,52]	4	9		
Temperature Related Dose 2 [N=104,52]	64	34		
Drowsiness Any Across Doses [N=104,53]	47	31		
Drowsiness Grade 3 Across Doses [N=104,53]	0	3		
Drowsiness Related Across Doses [N=104,53]	43	26		
Irritability Any Across Doses [N=104,53]	60	38		
Irritability Grade 3 Across Doses [N=104,53]	5	8		
Irritability Related Across Doses [N=104,53]	54	31		
Loss of appetite Any Across Doses [N=104,53]	54	35		
Loss of appetite Grade 3 Across Doses [N=104,53]	5	5		
Loss of appetite Related Across Doses [N=104,53]	49	29		
Temperature Any Across Doses [N=104,53]	79	41		
Temperature Grade 3 Across Doses [N=104,53]	5	10		
Temperature Related Across Doses [N=104,53]	70	37		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with medically-attended events (MAEs)

End point title	Number of subjects with medically-attended events (MAEs)
End point description:	
End point type	Secondary

End point timeframe:  
During the entire study period

End point values	GSK2340272A Formulation 1 Group	GSK2340272A Formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	104	53		
Units: Subjects				
MAEs	94	45		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with adverse events of specific interest (AESIs)/potential immune-mediated disease (pIMDs)

End point title	Number of subjects with adverse events of specific interest (AESIs)/potential immune-mediated disease (pIMDs)
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

During the entire study period

End point values	GSK2340272A Formulation 1 Group	GSK2340272A Formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	104	53		
Units: Subjects				
AESI(s)/pIMD(s)	0	0		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with normal or abnormal values of biochemical parameters

End point title	Number of subjects with normal or abnormal values of biochemical parameters
-----------------	---

End point description:

Biochemical parameters assessed were Alanine Amino Transferase (ALAT), Aspartate Amino Transferase (ASAT), Bilirubin, Creatinine and Blood Urea Nitrogen (BUN).

End point type	Secondary
----------------	-----------

End point timeframe:

At Day 0, Day 21 and Day 42.

End point values	GSK2340272A Formulation 1 Group	GSK2340272A Formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	104	53		
Units: Subjects				
ALAT Day 0 [N=104,53]	3	4		
ALAT Day 21 [N=104,52]	1	1		
ALAT Day 42 [N=103,53]	1	0		
ASAT Day 0 [N=104,53]	3	3		
ASAT Day 21 [N=104,52]	4	3		
ASAT Day 42 [N=103,53]	1	0		
Bilirubin Total Day 0 [N=104,53]	3	4		
Bilirubin Direct Day 0 [N=104,53]	3	4		
Bilirubin Total Day 21 [N=104,52]	2	1		
Bilirubin Direct Day 21 [N=104,52]	1	1		
Bilirubin Total Day 42 [N=103,53]	1	0		
Bilirubin Direct Day 42 [N=103,53]	1	0		
Creatinine Day 0 [N=104,53]	3	3		
Creatinine Day 21 [N=104,52]	1	2		
Creatinine Day 42 [N=103,53]	1	0		
BUN Day 0 [N=104,53]	3	4		
BUN Day 21 [N=104,52]	1	1		
BUN Day 42 [N=103,53]	1	0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with unsolicited adverse events (AEs)

End point title	Number of subjects with unsolicited adverse events (AEs)
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

During the 83-day period following first vaccination and the 62-day period following second vaccination

End point values	GSK2340272A Formulation 1 Group	GSK2340272A Formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	104	53		
Units: Subjects				
Any 3 AE(s)	98	47		
Grade 3 AE(s)	18	8		
Related AE(s)	12	8		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with serious adverse events (SAEs)

End point title	Number of subjects with serious adverse events (SAEs)
End point description:	
End point type	Secondary
End point timeframe:	
During the entire study period	

End point values	GSK2340272A Formulation 1 Group	GSK2340272A Formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	104	53		
Units: Subjects				
SAEs	2	6		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with vaccine response for serum neutralising antibodies

End point title	Number of subjects with vaccine response for serum neutralising antibodies
-----------------	--

End point description:

Vaccine response rate was defined as the percentage of vaccinees with a minimum 4-fold increase in titer at post-vaccination for neutralizing antibody response. For initially seronegative subjects, antibody titer  $\geq 1:32$  after vaccination; For initially seropositive subjects, antibody titer after vaccination  $\geq 4$  fold the pre-vaccination antibody titer. The strain assessed was Flu A/Neth/602/2009.

Since HI testing for Day 42 samples were not performed in the same run as Day 0/Day 21 samples and that the bridging acceptance criterion was not met for subject enrolled in Step 1, it was decided to analyze again the Days 0, 21 and 42 time points along with Month 11-12 data for both enrolment steps (which is visible in outcome measure "Vaccine response for neutralizing antibodies"). Hence, the data

presented in this OM (before re-run) and in the "Vaccine response for neutralizing antibodies" differ although the timeframes are the same.

End point type	Secondary
End point timeframe:	
At Days 21 and 42	

End point values	GSK2340272A Formulation 1 Group	GSK2340272A Formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	29		
Units: Subjects				
Flu A/Neth/602/2009, Day 21 [N=59,29]	34	18		
Flu A/Neth/602/2009, Day 42 [N=61,29]	60	29		

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Solicited AEs: during days 0-6 post-vaccination; Unsolicited AEs: during a 21 day follow-up period after the first vaccination and a 62-day follow-up period after the second vaccination (Days 0-84); SAEs: during the entire study period.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	13.1

### Reporting groups

Reporting group title	GSK2340272A Formulation 1 Group
Reporting group description: -	
Reporting group title	GSK2340272A Formulation 2 Group
Reporting group description: -	

Serious adverse events	GSK2340272A Formulation 1 Group	GSK2340272A Formulation 2 Group	
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 104 (1.92%)	6 / 53 (11.32%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Injury, poisoning and procedural complications			
Traumatic brain injury			
subjects affected / exposed	0 / 104 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Conjunctivitis			
subjects affected / exposed	1 / 104 (0.96%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 104 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchospasm			

subjects affected / exposed	0 / 104 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Viral rash			
subjects affected / exposed	0 / 104 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 104 (0.96%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchiolitis			
subjects affected / exposed	1 / 104 (0.96%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchopneumonia			
subjects affected / exposed	0 / 104 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenitis			
subjects affected / exposed	0 / 104 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media			
subjects affected / exposed	1 / 104 (0.96%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	GSK2340272A Formulation 1 Group	GSK2340272A Formulation 2 Group	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	103 / 104 (99.04%)	53 / 53 (100.00%)	
Nervous system disorders			
Somnolence			
alternative assessment type: Systematic			
subjects affected / exposed	47 / 104 (45.19%)	31 / 53 (58.49%)	
occurrences (all)	60	39	
General disorders and administration site conditions			
Pyrexia			
alternative assessment type: Systematic			
subjects affected / exposed	81 / 104 (77.88%)	43 / 53 (81.13%)	
occurrences (all)	100	55	
Pain			
alternative assessment type: Systematic			
subjects affected / exposed	54 / 104 (51.92%)	37 / 53 (69.81%)	
occurrences (all)	80	58	
Swelling			
alternative assessment type: Systematic			
subjects affected / exposed	38 / 104 (36.54%)	21 / 53 (39.62%)	
occurrences (all)	42	28	
Eye disorders			
Conjunctivitis			
alternative assessment type: Systematic			
subjects affected / exposed	6 / 104 (5.77%)	2 / 53 (3.77%)	
occurrences (all)	6	2	
Gastrointestinal disorders			
Diarrhoea			
alternative assessment type: Systematic			
subjects affected / exposed	15 / 104 (14.42%)	7 / 53 (13.21%)	
occurrences (all)	16	8	
Vomiting			
alternative assessment type: Systematic			
subjects affected / exposed	6 / 104 (5.77%)	9 / 53 (16.98%)	
occurrences (all)	7	10	
Respiratory, thoracic and mediastinal			

disorders			
Cough			
alternative assessment type: Systematic			
subjects affected / exposed	13 / 104 (12.50%)	7 / 53 (13.21%)	
occurrences (all)	13	8	
Asthma			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 104 (3.85%)	5 / 53 (9.43%)	
occurrences (all)	4	6	
Skin and subcutaneous tissue disorders			
Rash			
alternative assessment type: Systematic			
subjects affected / exposed	8 / 104 (7.69%)	0 / 53 (0.00%)	
occurrences (all)	8	0	
Erythema			
alternative assessment type: Systematic			
subjects affected / exposed	41 / 104 (39.42%)	27 / 53 (50.94%)	
occurrences (all)	53	40	
Psychiatric disorders			
Irritability			
alternative assessment type: Systematic			
subjects affected / exposed	61 / 104 (58.65%)	38 / 53 (71.70%)	
occurrences (all)	83	48	
Infections and infestations			
Upper respiratory tract infection			
alternative assessment type: Systematic			
subjects affected / exposed	59 / 104 (56.73%)	24 / 53 (45.28%)	
occurrences (all)	90	34	
Gastroenteritis			
alternative assessment type: Systematic			
subjects affected / exposed	12 / 104 (11.54%)	8 / 53 (15.09%)	
occurrences (all)	14	11	
Bronchitis			
alternative assessment type: Systematic			
subjects affected / exposed	12 / 104 (11.54%)	6 / 53 (11.32%)	
occurrences (all)	14	7	

Pharyngitis			
alternative assessment type: Systematic			
subjects affected / exposed	11 / 104 (10.58%)	2 / 53 (3.77%)	
occurrences (all)	13	2	
Laryngitis			
alternative assessment type: Systematic			
subjects affected / exposed	6 / 104 (5.77%)	3 / 53 (5.66%)	
occurrences (all)	7	3	
Otitis media			
alternative assessment type: Systematic			
subjects affected / exposed	6 / 104 (5.77%)	3 / 53 (5.66%)	
occurrences (all)	7	3	
Otitis media acute			
alternative assessment type: Systematic			
subjects affected / exposed	9 / 104 (8.65%)	1 / 53 (1.89%)	
occurrences (all)	10	2	
Respiratory tract infection			
alternative assessment type: Systematic			
subjects affected / exposed	5 / 104 (4.81%)	3 / 53 (5.66%)	
occurrences (all)	6	3	
Rhinitis			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 104 (3.85%)	3 / 53 (5.66%)	
occurrences (all)	4	4	
Tonsillitis			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 104 (1.92%)	3 / 53 (5.66%)	
occurrences (all)	2	3	
Metabolism and nutrition disorders			
Decreased appetite			
alternative assessment type: Systematic			
subjects affected / exposed	54 / 104 (51.92%)	35 / 53 (66.04%)	
occurrences (all)	69	47	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 April 2010	Amendment 5 Due to recent developments in the pandemic situation and following the feedback from the European authorities, the follow-up study FLU D-PAN H1N1-037 is no longer planned to be conducted. Therefore the protocol was amended to delete all references to this planned follow-up study.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported